Table 1 Syphilis serology test of serum and CSF in HIV-positive and HIV-negative patients
Age/gender/race | HIV | Serology | CSF Pa; Cb | CD4c | HIV-1 viral loadd | Last RPR | |
|---|---|---|---|---|---|---|---|
1 | 40/M/B | + | RPR+ (1:64); FTA-ABS+ | NR P:30; W:21 | 535 | 24,561 | NR (5 years) |
2 | 43/M/H | + | RPR+ (1:1024); FTA-ABS+ | FTA-ABS+ P:46; W:4 | 137 | >5,000,000 | 1:64 (15 months) |
3 | 20/M/H | + | RPR+ (1:2048); FTA-ABS+ | FTA-ABS+ P:97; W:189 | 376 | 189,089 | 1:16 (10 months) |
4 | 28/M/W | + | RPR+ (1:16,384); FTA-ABS+ | VDRL+ P:36; W:7 | 127 | 496,559 | 1:16 (1 year) |
5 | 27/M/H | + | RPR+ (1:512); FTA-ABS+ | VDRL+ P:79; W:18 | 134 | NA | NA |
6 | 48/M/W | + | RPR+ (1:64); FTA-ABS+ | FTA-ABS+ P:43; W:37 | 124 | 224,685 | NA |
7 | 49/M/H | + | RPR+ (1:64); FTA-ABS+ | NR P:25; W:3 | NA | NA | 1:8 (4 months) |
8 | 25/M/B | + | RPR+ (1:1024); FTA-ABS+ | NR P:20; W:0 | 134 | NA | NA |
9 | 46/M/H | + | RPR+ (1:1024); FTA-ABS+ | FTA-ABS+ P:23; W:1 | 371 | 117,779 | 1:64 (1 month) |
10 | 50/M/H | + | RPR+ (1:256); FTA-ABS+ | NA NA | 201 | NA | NA |
11 | 59/M/H | − | RPR+ (1:2); FTA-ABS+ | NR P:543; W:2 | 1:2 (1 month) | ||
12 | 63/M/H | − | RPR+ (1:2); FTA-ABS+ | NR P:63; W:1 | NA | ||
13 | 51/M/B | − | RPR+ (1:2); FTA-ABS+ | NR P:48; W:0 | NA | ||
14 | 52/M/H | − | RPR+ (1:2); FTA-ABS+ | NR P:50; W:3 | NR | ||
15 | 58/M/B | − | RPR+ (1:8); FTA-ABS+ | NR P:20; W:1 | 1:8 (6 months) | ||
16 | 55/M/O | − | RPR+ (1:2048); FTA-ABS+ | VDRL+ P:86; W:6 | 1:128 (1 year) |